C R Bard Inc (BCR) : Gavekal Capital reduced its stake in C R Bard Inc by 10.63% during the most recent quarter end. The investment management company now holds a total of 40,049 shares of C R Bard Inc which is valued at $8,802,770 after selling 4,765 shares in C R Bard Inc , the firm said in a disclosure report filed with the SEC on Oct 17, 2016.C R Bard Inc makes up approximately 3.01% of Gavekal Capital’s portfolio.
Other Hedge Funds, Including , Howland Capital Management reduced its stake in BCR by selling 50 shares or 4.58% in the most recent quarter. The Hedge Fund company now holds 1,042 shares of BCR which is valued at $227,844. C R Bard Inc makes up approx 0.02% of Howland Capital Management’s portfolio.
C R Bard Inc opened for trading at $219.41 and hit $220.91 on the upside on Friday, eventually ending the session at $219.8, with a gain of 0.52% or 1.14 points. The heightened volatility saw the trading volume jump to 4,51,340 shares. Company has a market cap of $16,145 M.
On the company’s financial health, C R Bard Inc reported $2.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $2.17. The company had revenue of $873.50 million for the quarter, compared to analysts expectations of $847.53 million. The company’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.10 EPS.
Investors should note that on Oct 12, 2016, C R Bard Inc announced a cash dividend of $0.2600. The company’s management has announced Oct 20, 2016 as the ex-dividend date and fixed the record date on Oct 24, 2016. The payable date has been fixed on Nov 4, 2016.
Many Wall Street Analysts have commented on C R Bard Inc. C R Bard Inc was Upgraded by Wells Fargo to ” Outperform” on Sep 16, 2016. Company shares were Reiterated by Deutsche Bank on Jul 27, 2016 to “Hold”, Firm has raised the Price Target to $ 240 from a previous price target of $234 .Company shares were Reiterated by Barclays on Jul 27, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 235 from a previous price target of $224 .
C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.